-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $8

Benzinga·11/04/2025 16:33:00
Listen to the news
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $7 to $8.